Overview

A Phase 2 Trial of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia (OP-724-H201)

Status:
Recruiting

Trial end date:
2025-06-30

Target enrollment:

Participant gender:

Summary

This is a phase 2 trial of foscenvivint in liver cirrhosis patients caused by HIV/HCV co-infection with hemophilia to evaluate the efficacy, safety and pharmacokinetics.

Phase:

Phase 2

Details

Lead Sponsor:

Kiminori Kimura, MD

Collaborator:

Japan Agency for Medical Research and Development